↓ Calculate your dosage
"The Most Controversial Anti-Aging Peptide Ever Made" — Dr. Alex Tatem, uploaded 2026-07-29, 21:01, ~41,000 views as of 2026-07-30. Metadata pulled live via yt-dlp --skip-download --print this session — not from memory. Why this is a YouTube embed, not a self-hosted file: the site's usual recipe (ffmpeg 2-pass compress → <25 MiB, self-hosted) works for the ~5–6 minute explainer clips already on this site (BPC-157, iron, retatrutide). At 21 minutes, fitting under Cloudflare's 25 MiB/file limit would force the bitrate down to roughly a quarter of what those clips use — the video would be visibly blocky. A clean embed at full source quality serves the reader better than a degraded self-hosted copy. Said plainly here rather than silently substituted.
0 of 4
Major RCTs That Beat Placebo
Barth syndrome (TAZPOWER), heart failure (MOTION/PROGRESS-HF), mitochondrial myopathy (MMPOWER-3), and dry AMD (ReCLAIM-2) — all four missed their pre-specified primary endpoint.
8
FDA Reviewers Said No
Internal FDA staff recommended against approval. Office leadership overruled them and approved it anyway under the accelerated pathway.
$800K
Per Year — Brand Name
Forzinity's US list price for the one approved indication (Barth syndrome, ≥30 kg patients), per FDA/company reporting.
$75–130
Same Molecule, Gray Market
Per 10 mg "research use only" vial online — no prescription, no FDA oversight of purity, sold outside the approved-drug system.
SS-31 is a small, cell-permeable tetrapeptide (alternating aromatic and cationic amino acids) originally designed at Cornell by Hazel Szeto and Peter Schiller as a mitochondria-targeted antioxidant. Unlike most drugs, it doesn't act on a receptor on the cell surface — it crosses cell and mitochondrial membranes and binds directly to cardiolipin, a phospholipid found almost exclusively on the inner mitochondrial membrane, where it helps organize the folds (cristae) that house the electron transport chain. Stealth BioTherapeutics licensed the molecule and has spent roughly two decades and at least eleven separate human trials trying to prove that stabilizing cardiolipin translates into a clinical benefit people can feel.
Mechanism 1 — Cardiolipin Binding
Cristae Preserved
In a rat model of cardiac ischemia-reperfusion, elamipretide bound cardiolipin and measurably reduced fragmentation of the inner mitochondrial membrane's cristae networks — the structural finding the whole drug class is built on. This is the clearest, most direct mechanistic evidence in the file.
Mechanism 2 — Comprehensive Review
517 Papers
A 2025 structural/mechanistic review lays out elamipretide's full pharmacology — cardiolipin stabilization, reduced reactive oxygen species, improved ATP synthesis efficiency — while noting the translational gap between clean mechanistic data and the repeated clinical trial misses described below.
Mechanism 3 — Neuroinflammation (Mouse)
Reversed Memory Deficit
In mice given lipopolysaccharide (an inflammatory challenge), SS-31 improved mitochondrial function and reversed both synaptic and memory impairment — one of the cleaner positive-outcome animal studies in the file, and the kind of result that fuels the longevity/cognition interest in the compound.
Mechanism 4 — Why Barth Syndrome Specifically
Direct Genetic Link
Barth syndrome is caused by a mutation in the tafazzin gene, which remodels cardiolipin. It is the one disease where "a drug that stabilizes cardiolipin" is a direct mechanistic match to the underlying genetic defect — which is why the approval, despite thin efficacy data, targeted this population specifically rather than a broader indication.
SS-31 is unusually well-tested in humans for a peptide on this site — 14 registered trials across five different diseases. The honest gap isn't a lack of trials. It's that none of the placebo-controlled ones hit their primary target.
Animal / Preclinical / In Vitro
Rodent, cell-culture, and mechanistic work. Consistent cardiolipin-binding and cristae-preservation signal across models.
Registered Human Trials
ClinicalTrials.gov, July 2026: Barth syndrome, HFrEF, HFpEF, mitochondrial myopathy, dry AMD, Fuchs corneal dystrophy, LHON, Friedreich's ataxia, healthy aging, renal/coronary reperfusion.
RCTs Beating Placebo on Primary Endpoint
Zero, across the four major placebo-controlled efficacy trials with published results (see table below).
This is the load-bearing section. Every major placebo-controlled trial is listed with its actual primary-endpoint result, not a marketing summary of it.
| # |
Study / PMID |
Disease |
n |
Primary Endpoint Result |
Outcome |
| 1 |
TAZPOWER · PMID 38602181 — 28-wk RCT crossover + 168-wk open-label extension |
Barth syndrome |
12 |
6-min walk test + fatigue score: not statistically different from placebo. Knee extensor strength (secondary): +63 N median gain by week 168 — but only measured in the unblinded extension. |
Mixed / became the FDA basis |
| 2 |
PROGRESS-HF (MOTION) · PMID 32068002 — Phase 2 RCT |
Heart failure, reduced EF |
71 |
Change in LV end-systolic volume at 4 weeks: no significant difference vs. placebo at either 4 mg or 40 mg dose. |
Missed primary |
| 3 |
MMPOWER-3 · PMID 37268435 — Phase 3 RCT |
Primary mitochondrial myopathy |
218 |
6-min walk distance (−3.2 m, p=0.69) and total fatigue score (p=0.37): no significant difference vs. placebo. Post-hoc subgroup with mtDNA replisome mutations showed a signal. |
Missed primary |
| 4 |
ReCLAIM-2 · PMID 39605874 — Phase 2 RCT |
Dry AMD / geographic atrophy |
176 |
Visual acuity and GA-area growth: did not meet statistical significance. Secondary "ellipsoid zone" photoreceptor measure: 43–47% slower degradation vs. placebo (nominal p<0.01, not the pre-registered primary). |
Missed primary, secondary signal |
| 5 |
ReNEW (Phase 3) · NCT06373731 |
Dry AMD (following ReCLAIM-2) |
~330 planned |
Active, not recruiting as of July 2026. No published results yet — included so readers can track it rather than assume it doesn't exist. |
In progress |
Reality check (honest reading): Across four independently registered, placebo-controlled trials in four different diseases over roughly a decade, elamipretide has not once beaten placebo on its own pre-specified primary endpoint. Every trial found something on a secondary or subgroup measure — muscle strength, photoreceptor preservation, a genetic subgroup — and each of those secondary signals became the basis for the next trial or, in Barth syndrome, for the approval itself. That pattern can honestly be read two ways: (1) the drug has a real, if modest, mitochondrial effect that these particular endpoints and trial designs aren't well-suited to detect, or (2) a well-funded, well-run drug program can rerun the same molecule through enough trials that some secondary measure eventually turns up positive by chance. Neither reading is proven. Both are worth holding at once — this page does not pick one for you.
Elamipretide hydrochloride, the FDA-approved active ingredient in Forzinity, is chemically the same sequence sold online as "research use only SS-31." The price gap between the two channels is the single largest number on this page.
FDA-Approved Brand
Forzinity (elamipretide HCl)
~$800K
per year · $15,000+ per 280 mg vial
40 mg SC daily · Barth syndrome only, ≥30 kg
Unregulated / T5
Gray-Market SS-31 Vials
$75–130
per 10 mg vial ($3–13/mg) · no Rx, no FDA purity oversight
Community protocols run $225–1,950+/month depending on the dose tier chosen (see calculator below)
Most Human RCTs
Ubiquinol / CoQ10 Supplement
$15–40
per month · oral, over the counter
Different mechanism (electron-transport-chain cofactor, not cardiolipin) — see this site's own
CoQ10 page for its evidence base
→ Cross-reference, this site
NAD+ / NMN Supplements
$40–80
per month · daily oral
Different mitochondrial-support mechanism (NAD+ salvage pathway)
Exercise (vigorous, 75–149 min/wk)
$0
zero direct cost
Hazard ratio 0.81 for all-cause mortality vs. no vigorous activity — about 19% lower, not a third. Maximal benefit around 150–300 min/wk vigorous or 300–600 min/wk moderate. 116,221 US adults, 30 years of follow-up, 47,596 deaths. An observational cohort, so this is association rather than a randomised effect — and it is still the best-evidenced mitochondrial-biogenesis intervention available.
💰 Follow the Money — Precisely Stated
This is the inverse of the usual story on this site. Most infographics here document a cheap, unpatentable compound getting buried because no company can profit from the trial. Elamipretide is the opposite case: a patent- and orphan-exclusivity-protected molecule that a single company spent roughly two decades and eleven-plus trials trying to get across the finish line — and, after four straight primary-endpoint misses, succeeded in one narrow indication and priced it at levels only an exclusivity-protected drug can command.
Stealth BioTherapeutics' incentive: after ~10 years and multiple trial failures across five diseases, the company needed one approval to survive as a business — a fact the trade press (BioPharma Dive, PharmaVoice interviews with CEO Reenie McCarthy) reported directly. That is a real, disclosed motive to push hard on thin data, stated in its precise form: a company under financial pressure has an incentive to seek the most favorable interpretation of ambiguous results — that is not the same claim as "the company falsified data," which nothing here supports.
FDA leadership's incentive: per the FDA's own Integrated Review of NDA 215244 and reporting on it, eight FDA staff reviewers recommended against approval — flagging that the pivotal trial was not placebo-controlled in its extension phase and that placebo patients improved almost as much as treated patients on the 6-minute walk test. FDA clinical team leader Charu Gandotra wrote that Stealth's data did not "provide substantial evidence of effectiveness to support traditional or accelerated approval." Office director Hylton Joffe overruled that recommendation and signed off, citing the disease's rarity and severity plus the 45%+ knee-strength gain seen in the unblinded extension. Separately, seven members of Congress and more than 80 physicians had written to FDA Commissioner Marty Makary urging faster action for a fatal pediatric disease with zero approved treatments — real, disclosed political and humanitarian pressure in the other direction.
The precise claim: this is not evidence the drug doesn't work, and it is not evidence of corruption. It is a documented case where regulatory leadership chose "approve now, confirm later" over its own reviewers' read of the data, for a fatal disease with no alternative — and where that choice then unlocked an $800,000/year price the exclusivity system, not the trial data, makes possible. Readers weighing gray-market use for an unapproved indication (longevity, general mitochondrial support) are relying on a molecule whose only regulatory approval rests on exactly this contested evidence base.
The FDA-approved dose (40 mg/day) exists for one disease, at one body-weight threshold, using a pre-mixed 80 mg/mL pharmaceutical solution — it is not a "longevity dose." The doses biohackers and telehealth peptide clinics actually report using are dramatically lower. Both are shown below, honestly labeled, with the calculator underneath doing the reconstitution math for whichever one you're looking at.
Community Entry
1 mg/day SC
The low end of what multiple peptide-clinic and telehealth write-ups describe as the "most consistent" community anti-aging cluster (reported range 0.1–5 mg/day). Not a trial dose.
Clinic / Wellness Standard
5 mg/day SC
The dose most often cited across telehealth "physician-directed" wellness protocols (reported ranges cluster 5–10 mg/day), typically 3–5x/week rather than daily. Physician-supervised, but not an FDA-recognized dose for any indication.
CLINICAL PRACTICE
FDA-Approved Trial Dose (Barth Syndrome Only)
40 mg/day SC
The Forzinity label dose — 8x to 40x higher than typical community protocols. Studied only in Barth syndrome patients ≥30 kg; reduced to 20 mg/day for severe renal impairment (eGFR <30). Shown here so readers see the real gap between the "FDA-approved" number quoted in marketing and what community protocols actually use.
TRIAL / FDA LABEL
Hard Contraindication
STOP
Known serious hypersensitivity to elamipretide or any FORZINITY excipient. Hypersensitivity reactions (rash, papular lesions, eczematous dermatitis, cough) have occurred from minutes to months after starting — this is on the FDA label, not a theoretical concern. If a serious reaction occurs, the label says do not re-dose.
FDA LABEL
SS-31's regulatory story is different from every other peptide on this site — it is the one that actually got an FDA approval, which makes its gray-market channel a genuinely different legal animal than BPC-157 or Epithalon's.
FDA — September 19, 2025
Accelerated Approval (Narrow)
FORZINITY is approved to
"improve muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg," under accelerated approval based on knee extensor muscle strength — an intermediate endpoint. The FDA's own label states:
"Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial." It is not approved for heart failure, mitochondrial myopathy, dry AMD, or any longevity/wellness use.
→ FDA-approved label (accessdata.fda.gov, primary document)
FDA — the Reviewer Dissent
8 Reviewers Recommended Against
Per FDA's own Integrated Review of NDA 215244 and Reuters/BioSpace reporting on it: eight FDA data reviewers, including clinical team leader Charu Gandotra, recommended against approval, citing that the pivotal trial did not beat placebo. Office director Hylton Joffe overruled them and approved the drug, citing disease severity and the open-label extension's strength data.
→ FDA Integrated Review (primary document) ·
→ BioSpace summary of Reuters reporting
Gray-Market / Research-Use Channel
Not the Approved Product
Because elamipretide is now an FDA-approved NDA drug (not a peptide still under 503A/PCAC review like BPC-157 or Epithalon), it was
not on the July 2026 PCAC compounding agenda. "Research use only" SS-31 sold online is legally distinct from Forzinity — no prescription, no FDA sterility/potency oversight, and independent testing of research-peptide vendors has repeatedly found underdosed or contaminated product in this category generally.
→ FDA 503A bulk substances page
WADA / Sports
Not Explicitly Listed — Ambiguous
Elamipretide does not appear by name on WADA's 2026 Prohibited List. Because it is now FDA-approved for a specific indication, some anti-doping analysts have flagged it as potentially falling outside the "non-approved substances" (S0) catch-all, while its mitochondrial/bioenergetic mechanism could theoretically draw S2 scrutiny in a future review. Bounded claim: we found no explicit S0/S2 listing as of July 2026 — athletes should confirm directly with their governing body before use, not rely on this page.
→ WADA Prohibited List 2026
Two equal pillars — the controlled trial record above, set against credentialed clinicians and the one physician who actually ran the pivotal patient cohort.
📚 What the Controlled Trials Show
Four separate placebo-controlled RCTs (Barth syndrome, HFrEF, mitochondrial myopathy, dry AMD) have each missed their primary efficacy endpoint. See the trials table above for the exact numbers.
Every one of those trials also turned up something on a secondary or subgroup analysis — muscle strength in Barth syndrome, photoreceptor preservation in dry AMD, a genetic subgroup in mitochondrial myopathy. Whether that pattern reflects a real, hard-to-measure effect or a well-resourced program finding a positive result somewhere eventually is exactly the open question this page can't resolve for you.
The mechanistic and animal literature is genuinely strong and consistent — cardiolipin binding and cristae preservation replicate across labs and species. That's not in dispute; what's in dispute is whether it translates to a felt clinical benefit at the doses and durations tested.
Safety data from the pivotal Barth trial (n=12) is real but small: 100% of treated patients had some local injection-site reaction vs. 67% on placebo — see the safety section below for the full FDA label breakdown.
🩺 What Practitioners Report
Dr. Hilary Vernon, MD, PhD — Associate Professor of Genetic Medicine, Johns Hopkins School of Medicine; Director, Barth Syndrome Interdisciplinary Clinic, Kennedy Krieger Institute. Credential independently verified via
Johns Hopkins Medicine's own faculty profile and
Kennedy Krieger's. Co-investigator on TAZPOWER, the trial that treated the actual 12-patient Barth syndrome cohort with elamipretide and published the real outcome numbers (PMID 38602181, 37041653). This is a genuine Pass-3 finding — a licensed clinician who treated real patients and co-published honest results, including the primary-endpoint miss, not just the favorable secondary numbers. Design limitation stated plainly by the same author group: the strength-gain data comes from the unblinded, single-arm extension period, not the placebo-controlled phase.
Dr. Alex Tatem (MD, per channel self-disclosure) —
"The Most Controversial Anti-Aging Peptide Ever Made" (2026-07-29, 21:01, ~41,000 views as of 2026-07-30). Frames SS-31 as mechanistically compelling but walks through the same repeated-trial-failure pattern documented above before FDA approval, then covers real-world dosing. No product sale detected in the description (a merch link for an unrelated apparel brand is present). Independent board/licensing verification not accessible from public sources — flagged accordingly, same as our treatment of this channel on other pages.
Dr. Ashley Froese, DO (primary care, Arizona — on this site's banked expert roster) —
"The Mitochondria Repair Peptide Your Doctor Has Never Heard About" (2026-07-25, 12:03, ~59,000 views as of 2026-07-30). Positions SS-31 as a tool for cardiolipin stabilization and chronic-fatigue-adjacent complaints.
Discloses a commercial interest: the video is sponsored by an unrelated electrolyte brand (LMNT) and links her own paid "Clinical Peptide Course" — disclosed here per this site's inline-disclosure rule.
Quinn Stillson, MD (credential per channel disclosure; independent licensing not accessible from public sources) —
"SS-31 (Elamipretide): FDA-Approved Mitochondrial Peptide" (2025-11-28, 26:52, ~86,000 views as of 2026-07-30). Covers the human and animal evidence and dosing directly; no product sponsorship detected in the description.
Real-World Use
Outside Barth syndrome, the people actually using SS-31 today are longevity-focused biohackers and telehealth "wellness" patients, drawn to it because it is one of the only peptides in this category with an actual FDA approval anywhere in its file — even though that approval doesn't cover their use case. Commonly reported anecdotal effects: subjective energy improvement, reduced post-exercise fatigue, and (per chronic-fatigue-focused practitioners like Dr. Froese) symptom relief in ME/CFS-adjacent presentations. None of this is backed by a placebo-controlled human trial in these populations — the trials that exist were run in sick, symptomatic populations (heart failure, mitochondrial disease, macular degeneration) and still missed their primary endpoints.
Removal asymmetry — Pass 8 note: Our yt-dlp search of "SS-31 elamipretide peptide" surfaced eight results, all currently live, spanning 2024–2026, from independent MDs, a longevity podcast, and peptide-education channels. No evidence of a removal or demonetization campaign against SS-31 content was found — bounded to this single search session. This differs from the removal patterns documented on some other peptides on this site; we report the absence honestly rather than assuming it.
Unlike most peptides on this site, SS-31/elamipretide has a real FDA label with real trial safety data behind it — quoted directly, not paraphrased.
Hypersensitivity — the Boxed Concern
Real, on Label
The FDA label's own language: "Hypersensitivity reactions, including serious allergic reactions requiring emergency medical intervention, have been reported... including skin manifestations such as rash, papular lesions, and eczematous dermatitis, as well as respiratory symptoms including cough. Reactions may occur within minutes to months after treatment initiation." Patients who've had a serious reaction should not be re-dosed. Contraindicated in anyone with known serious hypersensitivity to elamipretide or its excipients.
→ FDA label, Sections 4 & 5.2 (openFDA / accessdata.fda.gov)
Injection Site Reactions
100% vs. 67%
In the 12-patient Barth syndrome pivotal trial, 100% of elamipretide-treated patients had some local injection reaction (erythema 100% vs. 25% on placebo; induration 67% vs. 17%; pruritus 67% vs. 17%; pain 75% vs. 42%) — vs. 67% of placebo patients. This is real, FDA-tabulated data from a small trial; treat the exact percentages as n=12-sized, not population-level.
→ FDA label, Section 6.1, Table 2
Eosinophilia
Flagged ≥30 Days
The label notes increases in absolute eosinophil counts "noted frequently" in studies where dosing ran 30 days or longer — a lab finding worth monitoring on longer community cycles, not just the FDA-studied 12-week/168-week schedule.
→ FDA label, Section 6.1
Sourcing / Purity Risk
HIGH (gray-market)
Real FORZINITY is a sterile 80 mg/mL solution, refrigerated, discarded 8 days after opening, made under pharmaceutical manufacturing controls. A $75–130 "research use only" vial online has none of that oversight — no sterility testing requirement, no potency verification, no cold-chain guarantee. Independent testing of research-peptide vendors generally has repeatedly found under- or mis-dosed product.
→ FDA label, Section 16 (How Supplied/Storage) · vendor-testing pattern per market reporting
⛔ FDA label hard stops: (1) Known serious hypersensitivity to elamipretide or any excipient — do not use. (2) FORZINITY is not approved for intravenous use and is not approved for neonates — it contains 20 mg/mL of benzyl alcohol, which has caused fatal toxicity in low-birth-weight and preterm neonates when given IV. (3) If a serious hypersensitivity reaction occurs, discontinue and do not re-dose. (4) No trial has established a safe or effective dose for any use outside the approved Barth syndrome indication — every other use, including all community/longevity protocols, is off-label extrapolation.
✓ What seems reassuring (provisionally): No organ toxicity, overdose case, or drug-interaction signal was found in the FDA label or in our PubMed safety search. The dominant adverse effect across trials is local injection-site irritation — uncomfortable but not dangerous. Unlike some other peptides on this site, SS-31's mechanism (cardiolipin binding, not telomerase or hormone-pathway activation) has not produced a theoretical cancer-risk signal in the literature we reviewed. This is a genuinely well-tolerated molecule at the doses tested; the open question is efficacy, not safety.
An honest read of SS-31 in 2026
What it is: A lab-designed peptide that binds directly to cardiolipin, a fat molecule that helps organize the mitochondria's inner architecture. The chemistry is real and well-replicated in cells and animals. It is FDA-approved under the brand name Forzinity — but only for one ultra-rare pediatric disease (Barth syndrome), and only in patients heavy enough (≥30 kg) to qualify.
Who's using it: Two very different populations. A small number of genetically-confirmed Barth syndrome patients getting the real, pharmaceutical-grade, insurance-billed drug at $800,000/year. And a much larger, harder-to-count group of longevity biohackers and telehealth wellness patients buying the identical peptide sequence from research-chemical vendors for $75–130 a vial, at doses roughly a tenth to a fortieth of the approved trial dose, for uses the drug has never been tested for.
What the law says: Forzinity is a legitimate, FDA-approved prescription drug for its one indication. "Research use only" SS-31 sold online for any other purpose is not the approved product, is not legally compounded, and carries no FDA oversight of what's actually in the vial. Because elamipretide is now an approved NDA drug rather than an unapproved bulk peptide, it sits outside the 503A/PCAC compounding-pathway review that governs BPC-157, TB-500, GHK-Cu, and Epithalon on this site — a materially different, and in some ways murkier, legal position.
What the research shows: Four major placebo-controlled human trials, across four different serious diseases, have each failed to beat placebo on their primary endpoint. Every one of those same trials found a positive secondary or subgroup signal. FDA leadership overruled eight of its own reviewers to approve the drug anyway, in the narrowest possible indication, citing disease severity and the extension-phase strength data. That is a genuinely contested, well-documented regulatory judgment call — not proof the drug works, and not proof it doesn't.
- Zero of four major placebo-controlled RCTs have beaten placebo on their pre-specified primary endpoint — a real, repeated, documented pattern, not a single unlucky trial.
- The one FDA approval that exists is narrow (Barth syndrome, ≥30 kg), was granted over internal reviewer objections, and does not cover longevity, heart failure, fatigue, or any other off-label use people are actually buying it for.
- The $800,000/year brand price and the $75–130 gray-market vial are the same molecule in two different regulatory universes — know which one you're actually choosing between.
- Safety at studied doses looks genuinely mild — mostly injection-site irritation — but every gray-market dose and duration is off-label extrapolation with no trial behind it.
- Dr. Hilary Vernon's team at Johns Hopkins/Kennedy Krieger is the one group that has actually treated real Barth syndrome patients and published honest numbers, including the parts that didn't work.
- Not medical advice. This is an unusually well-litigated, well-documented drug file — read the primary FDA review before assuming either "approved" or "failed its trials" tells the whole story. Talk to your physician before using it for anything outside its approved indication.